INCY
Price
$67.86
Change
-$1.08 (-1.57%)
Updated
Jul 18 closing price
Capitalization
13.14B
9 days until earnings call
RPRX
Price
$35.59
Change
+$0.12 (+0.34%)
Updated
Jul 18 closing price
Capitalization
15B
16 days until earnings call
Interact to see
Advertisement

INCY vs RPRX

Header iconINCY vs RPRX Comparison
Open Charts INCY vs RPRXBanner chart's image
Incyte
Price$67.86
Change-$1.08 (-1.57%)
Volume$1.56M
Capitalization13.14B
Royalty Pharma
Price$35.59
Change+$0.12 (+0.34%)
Volume$2.02M
Capitalization15B
INCY vs RPRX Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. RPRX commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and RPRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (INCY: $67.86 vs. RPRX: $35.59)
Brand notoriety: INCY: Notable vs. RPRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 85% vs. RPRX: 44%
Market capitalization -- INCY: $13.14B vs. RPRX: $15B
INCY [@Biotechnology] is valued at $13.14B. RPRX’s [@Biotechnology] market capitalization is $15B. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileRPRX’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • RPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RPRX is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 3 TA indicator(s) are bullish while RPRX’s TA Score has 3 bullish TA indicator(s).

  • INCY’s TA Score: 3 bullish, 4 bearish.
  • RPRX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INCY is a better buy in the short-term than RPRX.

Price Growth

INCY (@Biotechnology) experienced а -1.06% price change this week, while RPRX (@Biotechnology) price change was -0.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

INCY is expected to report earnings on Jul 29, 2025.

RPRX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($15B) has a higher market cap than INCY($13.1B). INCY has higher P/E ratio than RPRX: INCY (339.30) vs RPRX (15.40). RPRX YTD gains are higher at: 41.380 vs. INCY (-1.752). RPRX has higher annual earnings (EBITDA): 2.02B vs. INCY (407M). INCY has more cash in the bank: 2.41B vs. RPRX (1.82B). INCY has less debt than RPRX: INCY (43.1M) vs RPRX (7.62B). INCY has higher revenues than RPRX: INCY (4.41B) vs RPRX (2.26B).
INCYRPRXINCY / RPRX
Capitalization13.1B15B87%
EBITDA407M2.02B20%
Gain YTD-1.75241.380-4%
P/E Ratio339.3015.402,204%
Revenue4.41B2.26B195%
Total Cash2.41B1.82B133%
Total Debt43.1M7.62B1%
FUNDAMENTALS RATINGS
INCY vs RPRX: Fundamental Ratings
INCY
RPRX
OUTLOOK RATING
1..100
6570
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8994
PRICE GROWTH RATING
1..100
5448
P/E GROWTH RATING
1..100
156
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (2) in the Pharmaceuticals Major industry is significantly better than the same rating for INCY (92) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than INCY’s over the last 12 months.

RPRX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as INCY (100) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.

INCY's SMR Rating (89) in the Biotechnology industry is in the same range as RPRX (94) in the Pharmaceuticals Major industry. This means that INCY’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as INCY (54) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for RPRX (56) in the Pharmaceuticals Major industry. This means that INCY’s stock grew somewhat faster than RPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYRPRX
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
48%
Momentum
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
68%
MACD
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
49%
Advances
ODDS (%)
Bullish Trend 11 days ago
60%
Bullish Trend 6 days ago
54%
Declines
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 4 days ago
62%
BollingerBands
ODDS (%)
N/A
Bearish Trend 5 days ago
64%
Aroon
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FALN27.000.04
+0.15%
iShares Fallen Angels USD Bond ETF
TIPZ53.010.03
+0.06%
PIMCO Broad US TIPS ETF
LIAQ219.13N/A
N/A
LifeX 2058 Infl-Prt Longevity Inc ETF
ADIV17.97-0.01
-0.04%
SmartETFs Asia Pcfc Dvdnd Bldr ETF
EWD44.65-0.33
-0.73%
iShares MSCI Sweden ETF

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with TECH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-1.57%
TECH - INCY
41%
Loosely correlated
-2.38%
AGIO - INCY
38%
Loosely correlated
-0.87%
REGN - INCY
38%
Loosely correlated
N/A
SYRE - INCY
38%
Loosely correlated
-3.55%
RPRX - INCY
37%
Loosely correlated
+0.34%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with INCY. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then INCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+0.34%
INCY - RPRX
36%
Loosely correlated
-1.57%
GLPG - RPRX
33%
Loosely correlated
+1.57%
SEER - RPRX
33%
Loosely correlated
-0.47%
XNCR - RPRX
31%
Poorly correlated
-1.10%
IMAB - RPRX
31%
Poorly correlated
-2.78%
More